Nanostics

Person Health Inc.Healthcare TechnologyUnited States

67% match

Person Health Inc. provides a preventive health-intelligence platform that combines differentiated diagnostics, person-centered data, and guided engagement to help clinicians and researchers recognize health risks earlier. Its initial focus is a research-use-only program centered on breast cancer detection using blood-based molecular fingerprinting, with plans to expand to non-invasive breath technologies and other diseases.

DIACEUTICS PLCDXRX · HealthtechBelfast, United Kingdom

65% matchPublic

Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.

Valius Health, Inc.HealthtechUnited States

64% match

Valius Health, Inc. provides comprehensive cancer diagnostic and tumor profiling services for patients and oncologists. The company analyzes tumor DNA, RNA, and proteins to identify actionable therapeutic targets and treatment options.

ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.

MDxHealth SA0O8G · BiotechHerstal, Belgium

70% matchPublic

MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.

EarlyDiagnostics, also known as EarlyDx, is a clinical-stage precision diagnostics company that develops non-invasive liquid biopsy technologies and genomics platforms for early cancer detection.